Company: MDCXW
Filing Date: 2025-04-25
Form Type: DRS
Source: 0001062993-25-007956
Chunk: 155

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-25
Form: DRS
Chunk 155
---
 sets out the Compensation Committee's responsibilities, including;

•making recommendations to the Board with respect to the size, composition and structure of the Board;

•making recommendations to the Board with respect to the reorganization of responsibilities among committees, the creation of additional committees or subcommittees, or the elimination of committees;

•making recommendations to the Board with respect to the preferred experience and qualifications of news directors to be elected by shareholders;

•making recommendations to the Board with respect to qualified candidates for nomination for election to the Board at each annual general meeting of shareholders;

•making recommendations to the Board with respect to the appointment of qualified directors to each committee;

•making recommendations to the Board with respect to developing and overseeing an orientation program for new directors and a continuing education program for current directors;

•making recommendations to the Board with respect to Board succession; and

•conducting annual performance assessments of the Board.

Executive Compensation

Named Executive Officers

Compensation of our named executive officers generally consists of the following elements: base salaries and participation in our equity incentive plan. The following table sets forth all compensation awarded to, or earned by, our named executive officers for the years ended December 31, 2024 and 2023.

| Name and                  
 principal position        
 Dr. Raza Bokhari, (1) CEO |  Fiscal Year 
        Ended 
 December 31, 
         2024 |  Salary 
     ($) 
       - | Share-based 
 Awards      
 ($)         
 -           | Option-based 
   Awards ($) 
      100,856 | Pension   
 Value ($) 
 -         |        All Other 
 Compensation ($) 
                - |        Total 
 Compensation 
          ($) 
      100,856 |
|:--------------------------|-------------:|--------:|:------------|-------------:|:----------|-----------------:|-------------:|
|                           |         2023 |       - | -           |      132,601 | -         |                - |      132,601 |
| James Quinlan,            
 CFO                       |         2024 | 318,269 | -           |       40,342 | -         |          125,000 |      483,611 |
|                           |         2023 |  93,969 | -           |       66,300 | -         |          100,000 |      260,269 |
| Dr. Edward Brennan,       
 CSO, CMO (2)              |         2024 | 325,